{
    "id": 25835,
    "fullName": "ROS1 S1986Y",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ROS1 S1986Y lies within the protein kinase domain of the Ros1 protein (UniProt.org). S1986Y has been demonstrated to occur as a secondary drug resistance mutation in the context of ROS1 fusions (PMID: 27401242), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Feb 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 7357,
                    "pubMedId": 27401242,
                    "title": "Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401242"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6098,
        "geneSymbol": "ROS1",
        "terms": [
            "ROS1",
            "c-ros-1",
            "MCF3",
            "ROS"
        ]
    },
    "variant": "S1986Y",
    "createDate": "12/20/2016",
    "updateDate": "02/21/2020",
    "referenceTranscriptCoordinates": {
        "id": 102478,
        "transcript": "NM_002944",
        "gDna": "chr6:g.117318236G>T",
        "cDna": "c.5957C>A",
        "protein": "p.S1986Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9639,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring EZR-ROS1 and ROS1 mutations, S1986Y and S1986F, demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) obtained through a Phase I/II trial, resulting in a partial response (PMID: 27401242; NCT01970865).",
            "molecularProfile": {
                "id": 26943,
                "profileName": "EZR - ROS1 ROS1 S1986F ROS1 S1986Y"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7357,
                    "pubMedId": 27401242,
                    "title": "Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401242"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9638,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring EZR-ROS1 demonstrated resistance to Xalkori (crizotinib) due to the acquired secondary resistance mutations, ROS1 S1986Y and ROS1 S1986F (PMID: 27401242).",
            "molecularProfile": {
                "id": 26943,
                "profileName": "EZR - ROS1 ROS1 S1986F ROS1 S1986Y"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7357,
                    "pubMedId": 27401242,
                    "title": "Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401242"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9646,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EZR-ROS1 and ROS1 S1986Y demonstrated sensitivity to Lorlatinib (PF-06463922) in culture (PMID: 27401242).",
            "molecularProfile": {
                "id": 26945,
                "profileName": "EZR - ROS1 ROS1 S1986Y"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7357,
                    "pubMedId": 27401242,
                    "title": "Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401242"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9651,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EZR-ROS1 and ROS1 S1986Y demonstrated resistance to treatment with Zykadia (ceritinib) in culture (PMID: 27401242).",
            "molecularProfile": {
                "id": 26945,
                "profileName": "EZR - ROS1 ROS1 S1986Y"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7357,
                    "pubMedId": 27401242,
                    "title": "Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401242"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9650,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EZR-ROS1 and ROS1 S1986Y demonstrated resistance to treatment with Xalkori (crizotinib) in culture (PMID: 27401242).",
            "molecularProfile": {
                "id": 26945,
                "profileName": "EZR - ROS1 ROS1 S1986Y"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7357,
                    "pubMedId": 27401242,
                    "title": "Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401242"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26941,
            "profileName": "ROS1 S1986Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26943,
            "profileName": "EZR - ROS1 ROS1 S1986F ROS1 S1986Y",
            "profileTreatmentApproaches": [
                {
                    "id": 16948,
                    "name": "Lorlatinib",
                    "profileName": "EZR - ROS1 ROS1 S1986F ROS1 S1986Y"
                }
            ]
        },
        {
            "id": 26945,
            "profileName": "EZR - ROS1 ROS1 S1986Y",
            "profileTreatmentApproaches": [
                {
                    "id": 16949,
                    "name": "Lorlatinib",
                    "profileName": "EZR - ROS1 ROS1 S1986Y"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102478,
            "transcript": "NM_002944",
            "gDna": "chr6:g.117318236G>T",
            "cDna": "c.5957C>A",
            "protein": "p.S1986Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}